Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

Abstract

This is the first study to document the clinical impact of frequent molecular monitoring, and the findings underscore the importance of regular molecular monitoring in delivering quality care for CML. These findings could be subject to unobserved confounders.